C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.

Abstract

PURPOSE:

Overall survival (OS) is the most significant endpoint for evaluation of treatment benefit with checkpoint inhibitors (CPI) in cancer. We evaluated serum C-reactive protein (CRP) in non-small cell lung cancer (NSCLC) trials with atezolizumab (anti-PD-L1) as an early OS surrogate.

METHODS:

Serum from patients enrolled in randomized Phase II (n = 240) and Phase III (n = 701) trials of NSCLC patients (POPLAR, OAK) who progressed on prior-platinum chemotherapy, were analyzed for CRP levels over time. Patients were grouped by changes in CRP levels post-treatment as either increased (≥ 1.5 fold), decreased (≤ 1.5 fold) or unchanged (within +1.5 fold) relative to pre-treatment levels to assess association with progression free survival (PFS) and OS.

RESULTS:

Decrease in serum CRP levels at 6 weeks relative to pre-treatment were observed in patients with RECIST1.1 based complete or partial responses (CR/PR) to atezolizumab whereas patients with disease progression (PD) demonstrated an increase in CRP levels in the Phase II POPLAR study, and confirmed in the Phase III OAK study. Decrease in serum CRP as early as six weeks post treatment predicted improved PFS and OS, even in patients who were determined as stable disease (SD) in their first scan. This effect was not observed in the chemotherapy arms.

CONCLUSION:

Modulation of serum CRP correlates with clinical outcome post-atezolizumab treatment. This routine lab test may provide utility in informing OS signals as early as 6 weeks post-initiation of therapy with CPIs in NSCLC.

• Authors: Namrata S Patil, Wei Zou, Simonetta Mocci, Alan Sandler, Marcus Ballinger, Susan Flynn, Marcin Kowanetz, Priti S Hegde
• Journal: PloS one (PLoS One) Vol. 16 Issue 2 Pg. e0246486 ( 2021) ISSN: 1932-6203 [Electronic] United States
• PMID: 33534859 (Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial)

Chemical References

• Antibodies, Monoclonal, Humanized
• Platinum
• atezolizumab
• C-Reactive Protein

Topics

• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal, Humanized (therapeutic use)
• C-Reactive Protein (metabolism)
• Carcinoma, Non-Small-Cell Lung (blood, drug therapy)
• Female
• Humans
• Lung Neoplasms (blood, drug therapy)
• Male
• Middle Aged
• Platinum (therapeutic use)
• ROC Curve